Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Heterogeneity of treatment effect of prophylactic pantoprazole in adult ICU patients: a post hoc analysis of the SUP-ICU trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Tracheostomy practice and timing in traumatic brain-injured patients: a CENTER-TBI study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Noninvasive respiratory support in the hypoxaemic peri-operative/periprocedural patient: a joint ESA/ESICM guideline

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Lactate versus acetate buffered intravenous crystalloid solutions: a scoping review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Evaluating Non-Statistically Significant Results From Trials in Practice-Reply

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

Vis graf over relationer

PURPOSE: The Stress Ulcer Prophylaxis in the Intensive Care Unit (SUP-ICU) trial compared prophylactic pantoprazole with placebo in 3291 adult ICU patients at risk of clinically important gastrointestinal bleeding (CIB). As a predefined subgroup analysis suggested increased 90-day mortality with pantoprazole in the most severely ill patients, we aimed to further explore whether heterogenous treatment effects (HTE) were present.

METHODS: We assessed HTE in subgroups defined according to illness severity by SAPS II quintiles and the total number of risk factors for CIB using Bayesian hierarchical models, and on the continuous scale using Bayesian logistic regression models with interactions. Estimates were presented as posterior probability distributions of odds ratios (ORs), probabilities of different effect sizes, and marginal effects plots.

RESULTS: We observed potential HTE for 90-day mortality according to illness severity (median subgroup OR range 0.90-1.09) with higher risk in the most severely ill, but not with different numbers of risk factors (1.00-1.02). We observed potential HTE of pantoprazole for clinically important events (0.86-1.18) and infectious adverse events (0.88-1.27) with higher risk in patients with greater illness severity and in those with more risk factors for CIB. Pantoprazole substantially and consistently reduced the risk of CIB with no indications of HTE (0.53-0.63).

CONCLUSIONS: In this post hoc analysis of the SUP-ICU trial, we found indications of HTE with increased risks of serious adverse events in patients with greater illness severity or more risk factors for CIB allocated to pantoprazole. These findings are hypothesis-generating and warrant further prospective investigation. CLINICALTRIALS.

GOV IDENTIFIER: NCT02467621.

OriginalsprogEngelsk
TidsskriftIntensive Care Medicine
Vol/bind46
Udgave nummer4
Sider (fra-til)717-726
Antal sider10
ISSN0342-4642
DOI
StatusUdgivet - apr. 2020

ID: 59134835